Aims and scope
Pediatric Rheumatology is the official publication of the Pediatric Rheumatology European Society (PReS). Submissions on the evaluation and treatment of non-surgical musculoskeletal syndromes and diseases in children and adolescents, particularly autoimmune and rheumatic diseases are welcomed.
Diseases and syndromes of particular interest include musculoskeletal pain syndromes, rheumatic fever and post-streptococcal syndromes, juvenile idiopathic arthritis, systemic lupus erythematosus, juvenile dermatomyositis, local and systemic scleroderma, Kawasaki disease, Henoch-Schonlein purpura and other vasculitides, sarcoidosis, inherited musculoskeletal syndromes, autoinflammatory syndromes, and others. Pediatric Rheumatology encourages submissions on educational advances, drug studies, laboratory and radiological evaluations, and outcome measures.
Pediatric Rheumatology began publishing as Pediatric Rheumatology Online Journal in 2003. For access to articles published prior to 2006, contact the Editorial team.
PReS are providing financial support to aid any authors who require assistance with the article processing charge (APC). Applicable authors would be charged a discounted article processing charge of £350 payable for articles accepted for publication.Authors who would like to apply for the reduced APC should contact the contact the Editorial team. Applicable authors can request this support during the submission process, stating payment via the PReS Shared Support option.
All articles published by Pediatric Rheumatology are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in Pediatric Rheumatology you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed Central license agreement.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Pediatric Rheumatology therefore levies an article-processing charge of £1870.00/$2680.00/€2170.00 for each article accepted for publication, plus VAT or local taxes where applicable.
If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
BMC provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service.
All articles published in Pediatric Rheumatology are included in:
- Current contents
- PubMed Central
- Science Citation Index Expanded
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.
Pediatric Rheumatology operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous. The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.
Submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board.
All manuscripts submitted to Pediatric Rheumatology should adhere to BioMed Central's editorial policies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Citing articles in Pediatric Rheumatology
Articles in Pediatric Rheumatology should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Pediatr Rheumatol [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Pediatr Rheumatol 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Appeals and complaints
If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure. For complaints that cannot be resolved with the Editor, the authors should contact the Publisher.
Why publish your article in Pediatric Rheumatology
Pediatric Rheumatology's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.
Speed of publication
Pediatric Rheumatology offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.
Online publication in Pediatric Rheumatology gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Pediatric Rheumatology are included in article alerts and regular email updates. Some may be highlighted on Pediatric Rheumatology’s pages and on the BioMed Central homepage.
In addition, articles published in Pediatric Rheumatology may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Pediatric Rheumatology. A list of articles recently press-released by journals published by BioMed Central is available here.
As an author of an article published in Pediatric Rheumatology you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BioMed Central license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.
Official journal of
Annual Journal Metrics
57 days to first decision for reviewed manuscripts only
54 days to first decision for all manuscripts
90 days from submission to acceptance
14 days from acceptance to publication
2.543 - 2-year Impact Factor
2.668 - 5-year Impact Factor
1.002 - Source Normalized Impact per Paper (SNIP)
0.729 - SCImago Journal Rank (SJR)
368 Altmetric mentions